• English
  • Deutsch
  • Log In
    Password Login
    Research Outputs
    Fundings & Projects
    Researchers
    Institutes
    Statistics
Repository logo
Fraunhofer-Gesellschaft
  1. Home
  2. Fraunhofer-Gesellschaft
  3. Scopus
  4. Adjunctive N-Acetylcysteine and Lung Function in Pulmonary Tuberculosis
 
  • Details
  • Full
Options
2024
Journal Article
Title

Adjunctive N-Acetylcysteine and Lung Function in Pulmonary Tuberculosis

Abstract
Background: Tuberculosis remains a global health concern, and half of cured patients have permanent lung injury. N-acetylcysteine (NAC) has shown beneficial antimicrobial, antioxidant, and immunomodulatory effects in preclinical tuberculosis models. We examined its effects on tuberculosis treatment outcomes. Methods: This prospective, randomized, controlled trial nested within the TB SEQUEL cohort study enrolled 140 adults with moderate or far-advanced tuberculosis. Participants were randomly assigned 1:1 to standard therapy with or without 1200 mg of oral NAC twice daily for days 1 to 112. Clinical evaluations, sputum culture, and spirometry were performed at specified intervals through day 168, after which participants returned to the TB SEQUEL cohort. The primary outcome was culture conversion. Secondary outcomes included whole-blood glutathione levels and lung function. RESULTS Participants were predominantly young, male, and human immunodeficiency virus 1-negative and had heavy sputum Mycobacterium tuberculosis (MTB) infection burdens. NAC increased glutathione levels (NAC · day interaction, 8.48; 95% confidence interval [CI], 1.93 to 15.02) but did not increase stable culture conversion (hazard ratio, 0.84; 95% CI, 0.59 to 1.20; P=0.33). NAC treatment was associated with improved recovery of lung function (NAC · month, 0.49 [95% CI, 0.02 to 0.95] and 0.42 [95% CI, -0.06 to 0.91] for forced vital capacity and forced expiratory volume in the first second, respectively, as percentages of predicted values). The effects of NAC on lung function were greatest in participants with severe baseline lung impairment and appeared to persist beyond the period of NAC administration. Rates of serious or grade 3 to 4 nonserious adverse events did not differ between the groups. Conclusions: Despite increasing whole-blood glutathione levels, NAC did not affect eradication of MTB infection in adults with pulmonary tuberculosis that was moderate to far advanced. Secondary outcomes of lung function showed changes that merit further investigation.
Author(s)
Wallis, Robert S.
The Aurum Institute
Sabi, Issa
National Institute for Medical Research Tanga
Lalashowi, Julieth M.
National Institute for Medical Research Tanga
Bakuli, Abhishek
Klinikum der Universität München
Mapamba, Daniel Adon
National Institute for Medical Research Tanga
Olomi, Willyhelmina
National Institute for Medical Research Tanga
Siyame, Elimina
National Institute for Medical Research Tanga
Ngaraguza, Beatrice
National Institute for Medical Research Tanga
Chimbe, Ombeni
National Institute for Medical Research Tanga
Charalambous, Salome
The Aurum Institute
Rachow, Andrea
Klinikum der Universität München
Ivanova, Olena
Klinikum der Universität München
Zurba, Lindsay J.
Education for Health Africa
Myombe, Bahati
National Institute for Medical Research Tanga
Kunambi, Revocatus
National Institute for Medical Research Tanga
Hoelscher- von Lovenberg, Michael
Fraunhofer-Institut für Translationale Medizin und Pharmakologie ITMP  
Ntinginya, Nyanda Elias
National Institute for Medical Research Tanga
Churchyard, Gavin John
The Aurum Institute
Journal
NEJM Evidence  
DOI
10.1056/EVIDOA2300332
Language
English
Fraunhofer-Institut für Translationale Medizin und Pharmakologie ITMP  
  • Cookie settings
  • Imprint
  • Privacy policy
  • Api
  • Contact
© 2024